Liang Zhou | Clinical Pharmacology | Best Researcher Award

Ms. Liang Zhou | Clinical Pharmacology | Best Researcher Award

Shanghai Henlius Biotech Inc., China

Ms. Liang Zhou is a distinguished clinical pharmacology professional with extensive experience in oncology drug development, pharmacokinetics, and translational research. She earned her Master’s degree in Drug Metabolism and Pharmacokinetics from the China Pharmaceutical University in 2008, which laid the foundation for her successful career in pharmaceutical sciences. Over the years, she has held progressive positions in leading global and Chinese organizations, including Associate Senior Scientist at Wuxi Apptec, Demo Chemist at Thermo Fisher Shanghai, Associate Director of Clinical Pharmacology at Mosim, and currently serves as the Senior Director of Clinical Pharmacology at Shanghai Henlius Biotech, Inc. since 2021. In these roles, she has contributed to more than 11 significant clinical trial programs across China, Australia, Japan, Europe, and the United States, with a strong focus on first-in-human (FIH) trials, PK/PD analysis, and oncology indications such as breast cancer, lymphoma, AML, NSCLC, gastric and pancreatic cancers, among others. Her research interests center on oncology drug development, dose exploration studies, biomarker integration, and regulatory science to accelerate access to novel therapies. With 23 academic documents, 91 citations, and an h-index of 4, Ms. Zhou demonstrates measurable scholarly impact, supported by her memberships in professional societies such as the Chinese Society of Clinical Oncology (CSCO). She has also enhanced her expertise through specialized training in GCP compliance, oncology drug development, and advanced pharmacometrics including R-language applications. Her skills encompass pharmacokinetic modeling, clinical trial design, regulatory submission, and team leadership, which collectively position her as a key figure in clinical pharmacology. Recognized for her contributions to cancer research and drug development, she continues to build a strong professional profile with the potential for international recognition. In conclusion, Ms. Liang Zhou’s blend of academic excellence, clinical research leadership, and commitment to advancing oncology therapeutics makes her a deserving candidate for prestigious awards and a driving force in global biomedical innovation.

Profile: Scopus

Featured Publications

Li, X., Zhang, Y., Wang, J., Chen, H., Zhou, L., Liu, M., … [et al.]. (2023). HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: An open-label, dose-escalation, phase 1 trial.(5)

Khadga Raj Aran | Pharmacology | Young Scientist Award

Khadga Raj Aran | Pharmacology | Young Scientist Award 

Research Scientist at ISF College of Pharmacy, Moga, India.

Dr. Khadga Raj Aran is a distinguished researcher in neuropharmacology, currently serving as an Associate Professor at ISF College of Pharmacy, Punjab, India. With a deep commitment to understanding the intricacies of neurological diseases, his work is largely focused on exploring neuroprotective therapies and pharmacological interventions. Dr. Aran has garnered several awards and international grants, reflecting his expertise and influence in his field. His contributions extend beyond academia to practical research applications, particularly in experimental pharmacology. Known for his dedication and innovative approach, Dr. Aran’s work has been presented at numerous global conferences, earning him significant recognition. His commitment to pharmacology research is demonstrated by his extensive hands-on skills in animal handling, sophisticated data analysis, and a keen interest in advancing neuropharmacological studies, especially those addressing neurodegenerative diseases. Dr. Aran’s career reflects both an impressive academic journey and a noteworthy dedication to impactful scientific discovery.

Profile

Scopus

Education

Dr. Khadga Raj Aran’s academic journey is marked by a strong foundation in pharmacology and neuropharmacology. He completed his Ph.D. in Pharmacology at the ISF College of Pharmacy, where he achieved a distinction with a high CPI score of 8.93. His research focused on neuroprotective agents against drug-induced neurological damage, which has become the foundation of his career. Prior to this, he earned his M.Pharm in Pharmacology, also with distinction, from the same institution. He holds a B.Pharm degree from East West College of Pharmacy under Rajiv Gandhi University of Health Sciences, Karnataka, where he graduated with honors. This comprehensive academic background has equipped Dr. Aran with a deep knowledge base and the technical skills necessary to excel in his research, making him a well-rounded expert in pharmacology with a keen specialization in neuropharmacology.

Professional Experience

Dr. Aran has accumulated a wealth of experience in pharmacology research and education. He currently holds the position of Associate Professor in the Department of Pharmacology at ISF College of Pharmacy. Previously, he worked as a Senior Research Fellow (SRF) funded by the Indian Council of Medical Research, where he honed his skills in handling complex neuropharmacological research. His early career included a Junior Research Fellowship at Sanjay Gandhi Postgraduate Institute of Medical Sciences. Dr. Aran’s research experience is diverse, encompassing animal handling, various laboratory techniques, and software proficiency for data analysis. His academic role allows him to mentor young scientists, while his research focuses on experimental neurology and pharmacology. Dr. Aran’s dedication and expertise have enabled him to contribute significantly to scientific understanding in these areas, presenting him as a thought leader in his field.

Research Interests

Dr. Aran’s research interests lie at the intersection of pharmacology and neuroscience, with a particular focus on neuroprotection and neurodegenerative diseases. His work explores therapeutic strategies for mitigating the harmful effects of pharmaceutical compounds on the brain, specifically targeting diseases like Parkinson’s and Alzheimer’s. Driven by a desire to contribute solutions to these critical health challenges, Dr. Aran investigates neuropharmacological agents and molecular pathways that could pave the way for new treatments. His research often utilizes advanced animal models and bioassays to study neurological responses, aiming to develop safer, more effective therapeutic options. This focus on neuroprotective pharmacology is fueled by a commitment to advancing public health and deepening scientific understanding of brain function and resilience.

Research Skills

Dr. Aran brings a comprehensive skill set to his neuropharmacology research. He has extensive experience in animal handling techniques across various species, such as rats, mice, and guinea pigs, which he employs for in-depth neurological studies. His proficiency extends to sophisticated laboratory techniques, including ELISA, HPLC-ECD, and stereotaxic surgeries, as well as blood collection and drug administration methods. Dr. Aran is skilled in using software such as GraphPad Prism, EndNote, and ChemDraw for data analysis and documentation, and he utilizes Photoshop and CorelDraw for diagrammatic representations. His research toolkit is completed by a solid command of statistical software like SPSS, enabling him to conduct rigorous data analysis and produce reliable results. These advanced research skills highlight his capability to conduct complex pharmacological studies with precision and accuracy.

Awards and Honors

Throughout his career, Dr. Khadga Raj Aran has received numerous accolades for his scientific contributions and research excellence. Among his prestigious achievements is a best design patent awarded by the Government of India, reflecting his innovative approach to pharmacological research. Dr. Aran has also been recognized internationally, receiving the Best Scholar Award from the International Scientist Awards for his contributions to Engineering, Science, and Medicine. His exceptional review work for the International Journal of Biochemistry Research and Review earned him a Certificate of Excellence in Reviewing. He has further demonstrated his scholarly impact through multiple travel grants for presenting research abroad, including grants from the IBRO and MDS International Congress. Each of these honors underscores Dr. Aran’s dedication to advancing pharmacology, establishing him as a leading figure in neuropharmacology research.

Conclusion:

Dr. Khadga Raj Aran is a strong candidate for the Research for Young Scientist Award due to his solid educational background, research experience, and contributions to neuropharmacology. His achievements, including travel grants, conference awards, and active involvement in national and international research organizations, underscore his potential to make significant contributions to the field. With continued research and collaboration efforts, Dr. Aran has the potential to achieve greater recognition and impact within the scientific community, making him a deserving recipient of the award.

Publications Top Notes

“Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders”
Authors: Bala, K., Porel, P., Aran, K.R.
Year: 2024
Journal: Psychopharmacology, Volume 241, Issue 10, Pages 1939–1954
Citations: 0

“Lansoprazole induces hippocampal cell apoptosis and impairs learning and memory functions via activation of tau phosphorylation and Aβ (1–42) pathway in adult rats”
Authors: Aran, K.R., Gupta, G.D., Singh, S.
Year: 2024
Journal: Toxicology and Environmental Health Sciences
Citations: 0

“Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease–A step towards mitochondria based therapeutic strategies”
Authors: Aran, K.R., Singh, S.
Year: 2023
Journal: Aging and Health Research, Volume 3, Issue 4, Article 100169
Citations: 2

“Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats”
Authors: Aran, K., Gupta, G., Singh, S.
Year: 2023
Journal: Asian Pacific Journal of Tropical Biomedicine, Volume 13, Issue 7, Pages 296–305
Citations: 0

“Amelioration of Cognitive Deficit by Cryptotanshinone in a Long-term Utilisation of Proton Pump Inhibitor-Induced Alzheimer’s Disease-Like Condition in a Rat Model”
Authors: Aran, K.R., Das Gupta, G., Singh, S.
Year: 2023
Journal: Revista Brasileira de Farmacognosia, Volume 33, Issue 3, Pages 595–609
Citations: 2